A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

Summary

Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform Rash

Timeline

Start

2021-05-04

Primary completion

2021-12-13

Completion

2021-12-13

Outcome

Outcome not reported

Stopped: “Administrative Reason”

Drugs

Indications